Subscribe to RSS
Clinical and Laboratory Evaluations of Patients Diagnosed as Having Multisystem Inflammatory Syndrome Associated with Coronavirus Disease 2019 in Children: A Single Center Experience from Konya
Objective Multisystem inflammatory syndrome in children (MIS-C), characterized by fever, inflammation, and multiorgan dysfunction, was newly defined after severe acute respiratory syndrome coronavirus 2 infection. The clinical spectrum of MIS-C can be classified as mild, moderate, and severe. We aimed to evaluate demographics, clinical presentations, laboratory findings, and treatment modalities of patients with MIS-C according to clinical severity.
Methods We performed a retrospective study of patients who were diagnosed as having MIS-C between September 2020 and October 2021 in the Necmettin Erbakan University Meram Faculty of Medicine, Türkiye.
Results A total of 48 patients (24 females and 24 males) with a median age at diagnosis of 10.3 years (range: 42 months–17 years) were enrolled, the most common clinical severity of MIS-C was moderate. The common presentations of patients were fever (97%), nonpurulent conjunctivitis (89.6%), rashes (81.3%), fatigue (81.3%), strawberry tongue (79.2%), and myalgia (68.8%). The most common laboratory findings were lymphopenia (81.2%), thrombocytopenia (54.1%), elevated D-dimer levels (89.5%), C-reactive protein (CRP; 100%), procalcitonin (97%), erythrocyte sedimentation rate (87.5%), ferritin (95.8%), interleukin 6 (IL-6) (86.1%), and probrain natriuretic peptide (pro-BNP) (97%). High levels of CRP, procalcitonin, pro-BNP, and urea were associated with the severity of MIS-C (p < 0.05). Fifteen of the patients were found to have pulmonary involvement. Ascites were the most common finding on abdominal ultrasonography (11 patients) and were not seen in a mild form of the disease. During the study period, two patients died.
Conclusion It is important to make patient-based decisions and apply a stepwise approach in treating patients with MIS-C due to the increased risk of complications and mortality.
KeywordsMultisystem inflammatory syndrome in children - COVID-19 - clinical and laboratory findings
Received: 14 July 2022
Accepted: 13 October 2022
Article published online:
26 November 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Kole MT, Yükselmiş U, Genç FA. et al. Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: a single-center experience. J Pediatr Infect Dis 2022; 17 (04) 200-208
- 2 Centers for Disease Control and Prevention. Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States. Published August 29, 2022. Accessed September 8, 2022 at: https://covid.cdc.gov/covid-data-tracker/#mis-national-surveillance
- 3 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383 (04) 334-346
- 4 Williams V, Dash N, Suthar R. et al. Clinicolaboratory profile, treatment, intensive care needs, and outcome of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2: a systematic review and meta-analysis. J Pediatr Intensive Care 2020; 11 (01) 1-12
- 5 Gruber CN, Patel RS, Trachtman R. et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell 2020; 183 (04) 982-995.e14
- 6 Godfred-Cato S, Bryant B. et al. California MIS-C Response Team. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020; 14;69 (32) 1074-1080
- 7 Jonat B, Gorelik M, Boneparth A. et al. Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children's hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up. Pediatr Crit Care Med 2021; 22 (03) e178-e191
- 8 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395 (10237): 1607-1608
- 9 Morris SB, Schwartz NG, Patel P. et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection—United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (40) 1450-1456
- 10 Miller AD, Zambrano LD, Yousaf AR. et al; MIS-C Surveillance Authorship Group. Multisystem inflammatory syndrome in children-united states, February 2020-July 2021. Clin Infect Dis 2022; 75 (01) e1165-e1175
- 11 Reiff DD, Cron RQ. Performance of cytokine storm syndrome scoring systems in pediatric COVID-19 and multisystem inflammatory syndrome in children. ACR Open Rheumatol 2021; 3 (12) 820-826
- 12 Alkan G, Sert A, Oz SKT, Emiroglu M, Yılmaz R. Clinical features and outcome of MIS-C patients: an experience from Central Anatolia. Clin Rheumatol 2021; 40 (10) 4179-4189
- 13 Whittaker E, Bamford A, Kenny J. et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324 (03) 259-269
- 14 Dufort EM, Koumans EH, Chow EJ. et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020; 383 (04) 347-358
- 15 Ucan B, Kaynak Sahap S, Cinar HG. et al. Multisystem inflammatory syndrome in children associated with SARS-CoV-2: extracardiac radiological findings. Br J Radiol 2022; 95 (1129): 20210570
- 16 Winant AJ, Blumfield E, Liszewski MC, Kurian J, Foust AM, Lee EY. Thoracic imaging findings of multisystem inflammatory syndrome in children associated with COVID-19: what radiologists need to know now. Radiol Cardiothorac Imaging 2020; 2 (04) e200346
- 17 Wu EY, Campbell MJ. Cardiac manifestations of multisystem inflammatory syndrome in children (MIS-C) following COVID-19. Curr Cardiol Rep 2021; 23 (11) 168
- 18 Ramcharan T, Nolan O, Lai CY. et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol 2020; 41 (07) 1391-1401
- 19 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol 2021; 73 (04) e13-e29
- 20 Kwak JH, Lee SY, Choi JW. Korean Society of Kawasaki Disease. Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Clin Exp Pediatr 2021; 64 (02) 68-75
- 21 Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. Pediatr Infect Dis J 2020; 39 (11) e340-e346